Drs. Andrew A. George and Ronald J. Lukas of the Barrow Neurological Institute have been awarded a National Institutes on Aging grant to investigate sites and mechanisms of oligomeric amyloid-β action at a unique α7β2-nicotinic acetylcholine receptor (α7β2-nAChR) subtype. Continue reading
Category Archives: AZBio News
Alzheimer’s Disease Data Initiative Launches, Critical Path for Alzheimer’s Disease Consortium to Partner
CPAD will partner with ADDI to build better tools for researchers around the world to access, use and share dementia-related data to accelerate the development of new and more effective treatments for Alzheimer’s disease
TUCSON, Ariz., November 17, 2020 — The Critical Path Institute’s (C-Path) Critical Path for Alzheimer’s Disease (CPAD) Consortium today announced its participation as a Partner with the Alzheimer’s Disease Data Initiative (ADDI), a 501(c)(3) medical research organization which launched today. ADDI is dedicated to advancing scientific breakthroughs in the treatment of Alzheimer’s disease (AD) and related dementias.Continue reading
PhRMA Announces First-Ever, Industry-Wide Principles on Clinical Trial Diversity
“The industry’s new clinical trial diversity principles are an important step toward greater health equity,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “We are addressing issues of mistrust and working to reduce systemic issues that deter communities of color from participating in clinical trials, so that those patients who want to participate, can.”
Continue reading
Nixxi Launches the First Widely Available Digital Health Screening Tool for Preterm Birth
Nixxi’s PopNatal™ offers the earliest and most cost-effective identification of women at risk for premature delivery.Continue reading
Opportunity Alert: Tour the New Wexford Science + Technology Building on the Phoenix Biomedical Campus
OPEN INVITATION FOR TOURS – 850 N 5TH STREET INNOVATION CENTER BY WEXFORD SCIENCE + TECHNOLOGYContinue reading
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
- First interim analysis included 95 participants with confirmed cases of COVID-19
- Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001)
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 monthsContinue reading
Managing the microbiome raises new hope for autism
In new research appearing in the journal mSphere, Rosa Krajmalnik-Brown, James Adams and their colleagues highlight the crucial importance of bacterial microbes in the human gut for the diagnosis and treatment of ASD.
In September of 2020, Rosa Krajmalnik-Brown was honored as the Arizona Bioscience Researcher of the Year
Continue reading
GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors
- Study to Enroll 600 Patients and Evaluate Real-World Clinical and Patient Reported Outcomes Across All Brain Tumor Types
- First Patient Enrolled by Vidant Health in Greenville, N.C.
Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
- Bamlanivimab is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients
- U.S. government will allocate 300,000 doses of bamlanivimab to high-risk patients, with no out-of-pocket costs for the medication
Brain State Technologies® and Cereset® Announces Promotion of Russell Scholl to President and Chief Financial Officer
The company’s CFO has been instrumental to the company’s success.Continue reading